AIAI predicts an enzymes substrateA new machine learning model can predict enzyme-substrate pairs, with an accuracy of over 90% and is ready to be used in pharmaceutical and industrial biotechnology. more ➔
decarbonisationLanzaTech and Plastipak produce greener PE...Carbon-capture specialist LanzaTech Global and Plastipak Packaging Inc have produced the worlds first PET resin made from captured carbon emissions. more ➔
Multiple sclerosisRoches meets endpoints in relapsing mult...Roche’s brutons tyrosine kinas blocker fenebrutinib has met all endpoints in proof-of-concept study with patients suffering from relapsing-remitting multiple sclerosis. more ➔
CGTuniQure sells royalty interest in gene the...uniQure N.V. is to sell a portion of its royalty rights from the net sales o its hemophilia B gene therapy etranacogene dezaparvovec-drbl to HealthCare Royalty and Sagard Healthcare for a gross purchase … more ➔
financingDualyx NV raises €40m in Series A financ... Belgian T reg specialist Dualyx NV had raised €40m to progress its three preclinical Treg candidates for autoimmune diseases into the clinic. more ➔
RSVSanofi’s/Astazeneca’s anti-RSV...NHS research partners of AstraZeneca and Sanofi have reported a 83% reduction in RSV infant hospitalisations in a post-approval clinical trial. more ➔
partnershipMainz Biomed Partners with Microba Life Sc...Molecular diagnostics specialist Mainz Biomed NV has inked a research collaboration with precision microbiome firm Microba Life Sciences Inc. more ➔
financingDiogenX SA raises €27.5M in Series A fin... French pancreatic beta-cell modulator specialist DiogenX SA has raised €27.5m in a Series A financing led by Boehringer Ingelheim Venture Fund and Roche Venture Fund. more ➔
M&AWacker AG expands biotech business through...Munich-based Wacker Group has purchased all shares of the Spanish CMO ADL BioPharma from financial investor Kartesia for €100m. more ➔
partnershipNeogap Therapeutics AB partners with Celle...Swedish AI specialist Neogap Therapeutics AB will secect antigens for Cellerys AG, which wants to establish immune tolerance in a Phase II MS trial. more ➔
